Union Bancaire Privee UBP SA Reduces Stock Holdings in Boston Scientific Corporation $BSX

Union Bancaire Privee UBP SA lessened its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 3.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 216,072 shares of the medical equipment provider’s stock after selling 7,862 shares during the period. Union Bancaire Privee UBP SA’s holdings in Boston Scientific were worth $21,073,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in BSX. Brighton Jones LLC raised its stake in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after buying an additional 226 shares during the period. Legacy Financial Advisors Inc. raised its position in shares of Boston Scientific by 4.8% during the 1st quarter. Legacy Financial Advisors Inc. now owns 5,576 shares of the medical equipment provider’s stock worth $563,000 after purchasing an additional 256 shares during the last quarter. Sumitomo Mitsui Financial Group Inc. lifted its stake in Boston Scientific by 36.4% in the 1st quarter. Sumitomo Mitsui Financial Group Inc. now owns 205,642 shares of the medical equipment provider’s stock valued at $20,745,000 after buying an additional 54,832 shares in the last quarter. Groupama Asset Managment lifted its stake in Boston Scientific by 13.7% in the 1st quarter. Groupama Asset Managment now owns 1,300,910 shares of the medical equipment provider’s stock valued at $129,258,000 after buying an additional 156,979 shares in the last quarter. Finally, Banco Bilbao Vizcaya Argentaria S.A. boosted its holdings in Boston Scientific by 1.1% in the 1st quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 77,781 shares of the medical equipment provider’s stock worth $7,845,000 after buying an additional 843 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,739,678.74. The trade was a 21.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 143,095 shares of company stock valued at $14,228,950 in the last 90 days. Company insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. The Goldman Sachs Group reissued a “buy” rating and set a $124.00 target price on shares of Boston Scientific in a report on Wednesday, October 22nd. Leerink Partners increased their price objective on Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. UBS Group lifted their target price on shares of Boston Scientific from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Truist Financial increased their target price on shares of Boston Scientific from $129.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Finally, Barclays raised their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $125.40.

Boston Scientific Stock Up 0.8%

Shares of BSX opened at $92.93 on Wednesday. Boston Scientific Corporation has a 52-week low of $85.98 and a 52-week high of $109.50. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The stock has a fifty day simple moving average of $98.70 and a two-hundred day simple moving average of $101.42. The company has a market capitalization of $137.76 billion, a PE ratio of 49.70, a price-to-earnings-growth ratio of 1.86 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter in the previous year, the company posted $0.63 EPS. The company’s revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.